338 related articles for article (PubMed ID: 24982341)
1. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
[TBL] [Abstract][Full Text] [Related]
3. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.
Sacchi M; Vitolo D; Sedlmayr P; Rabinowich H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1991 Mar; 47(5):784-91. PubMed ID: 2004859
[TBL] [Abstract][Full Text] [Related]
6. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
7. First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.
Strasnick B; Lagos N; Lichtenstein A; Mickel RA
Otolaryngol Head Neck Surg; 1990 Oct; 103(4):537-49. PubMed ID: 2123311
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor activity of adherent LAK cells (A-LAK) in a model of squamous carcinoma of the head and neck].
Sacchi M; Galeazzi E; Johnson JT; Cavalot AL; Cortesina G
Acta Otorhinolaryngol Ital; 1991; 11(4):405-15. PubMed ID: 1792895
[TBL] [Abstract][Full Text] [Related]
9. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
Bugis SP; Lotzová E; Savage HE; Hester JP; Racz T; Sacks PG; Schantz SP
Cancer Immunol Immunother; 1990; 31(3):176-81. PubMed ID: 2337906
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of head and neck tumor cell colony growth by lymphokine activated killer cells.
Kumazawa H; Kita J; Sai S; Tachikawa T; Hori Y; Yamazaki N; Yamashita T; Kumazawa T; Kawamoto K; Koldovsky P
Acta Otolaryngol Suppl; 1993; 500():138-41. PubMed ID: 8452012
[TBL] [Abstract][Full Text] [Related]
14. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
15. Longer local retention of adoptively transferred T-LAK cells correlates with lesser adhesion molecule expression than NK-LAK cells.
Yamamoto T; Yoneda K; Osaki T; Yoshimura N; Akagi N
Clin Exp Immunol; 1995 Apr; 100(1):13-20. PubMed ID: 7697911
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy.
Khurana D; Martin EA; Kasperbauer JL; O'Malley BW; Salomao DR; Chen L; Strome SE
Head Neck; 2001 Oct; 23(10):899-906. PubMed ID: 11592238
[TBL] [Abstract][Full Text] [Related]
17. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
18. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
[TBL] [Abstract][Full Text] [Related]
19. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of adoptive immunotherapy for adenoid cystic carcinoma of the salivary gland].
Li X; Zhou Z; Peng Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 1996 Sep; 31(5):271-3. PubMed ID: 9592252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
